Real‐World Safety of Concomitant Colchicine and Statin Therapy
Authors' conclusion
Although colchicine-statin concomitant therapy was associated with higher rates of laboratory and clinical adverse events, the additional risk beyond statin monotherapy was small
Study context
- Population
- Adults with gout or familial Mediterranean fever, 2010–2024, Clalit Health Services (≈5.4 million insured individuals)104,066 before matching
- Participants
- 31,839 adults
- Exposure
- Concomitant colchicine-statin therapy vs colchicine only, statin only or no treatment
- No treatmentn = 7,146reference
- Colchicine onlyn = 7,146
- Statin onlyn = 9,030
- Concomitant therapyn = 8,517
- Outcome
- Creatine kinase (CK) elevation >3× upper limit of normal (ULN)
Methodological detailspropensity-score matched, national Clalit Health Services database
- Propensity-score matched
- National Clalit Health Services database
Main finding
As reported in the abstract
Each group vs no treatmentHazard ratio (95% CI)
Statin only
1.64(1.39–1.93)
Concomitant therapy
1.74(1.44–2.09)
Colchicine only
1.08(0.89–1.31)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Clinically diagnosed myopathyConcomitant therapyvs No treatmentHighest risk; reference group not stated | 1.50 (1.31–1.72) | |
| 0.512Hazard ratio (log scale) |
Clinically diagnosed myopathy
- Infrequent, with a graded increase across exposure groups
Original publication
Real‐World Safety of Concomitant Colchicine and Statin Therapy. Arthritis Care Res (Hoboken). Published 28 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →